Alterity Therapeutics Ltd. Sponsored ADR Stock

$3.14

0.29% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Alterity Therapeutics Ltd. Sponsored ADR Stock price

$3.14

-5.26 62.62% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.01 0.29%

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$27.84m
Enterprise Value	$19.51m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	2.98
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-15.50m
Free Cash Flow (TTM) Free Cash Flow	$-8.30m
EPS (TTM) EPS	$-2.06
P/E forward	negative
Short interest	0.02%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Alterity Therapeutics Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Alterity Therapeutics Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Alterity Therapeutics Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Alterity Therapeutics Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.10 0.10	43% 43% -
Gross Profit	-0.10 -0.10	43% 43% -
- Selling and Administrative Expenses	3.07 3.07	11% 11% -
- Research and Development Expense	12 12	38% 38% -
EBITDA	-15 -15	24% 24% -
- Depreciation and Amortization	0.10 0.10	43% 43% -
EBIT (Operating Income) EBIT	-15 -15	24% 24% -
Net Profit	-13 -13	35% 35% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Alterity Therapeutics Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

25 days ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerat...

Neutral

GlobeNewsWire

●

about one month ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 No...

Neutral

GlobeNewsWire

●

about 2 months ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity's Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history ...

More Alterity Therapeutics Ltd. Sponsored ADR News

Company Profile

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Head office	Australia
CEO	David Stamler
Employees	10
Founded	1997
Website	www.alteritytherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now